RESIST will strengthen the resilience and accelerate the transformation and increase adaptive capacity of 12 climate-vulnerable EU regions, implementing 4 large-scale demonstrators of resilient innovations for Climate Change Adaptation (CCA) with quintuple-helix partnerships (including 1 in a less developed region) and promote transfer of know-how and innovative solutions to 8 twin regions (of which 4 less developed regions) through both physical mutual-learning activities and innovative immersive digital twins. The consortium will engage EU associations, CCA research groups, scientific experts, social engagement and communication institutions, innovation agencies and 1 Venture Capital Fund to co-create and validate innovative solutions, raise awareness, leverage citizens participation and promote sustainable exploitation of results towards the markets. RESIST will contribute to the EU agenda on CCA, through intervention in 3 main areas: Promote and demonstrate an innovative, more participative approach to resilience and CC adaptation in 4 demonstrator and 8 twinning regions (including 5 less developed regions in total) demonstrating >12 new solution lines, accelerating regional resilience and helping reach the adaptation-mission objectives of ‘building resilience and upscaling solutions through 100 demonstrators and accelerating the transition in 200 pilot regions and communities by 2030’ reaching already 4% and 6% of these aims by 2027, with 4 demonstrators and involvement of 12 regions Co-design and contribute to the development of new regional measures, policy instruments and social and technological solutions in 12 regions involving 22m citizens, increasing awareness/resilience by 10% and levels of green investments by 20%, reducing economic losses due to natural hazards such as floods by 14% and climate protection gap by 50%; Reduce time-to-market/risk for >100 new CCA Solutions from providers across Europe, offering them scale-up for their products.

The main objective of the proposal is to contribute to a better harmonisation and synchronisation of priority-setting-, funding- evaluation and life-cycle management of Research Infrastructures (RI through the exchange of best practices among the main stakeholders in member states, associated countries and at European level. The regional dimension will explicitly be taken into account by integrating, where appropriate, smart specialisation strategies in the work carried out. InRoad will achieve this by a) the identification and dissemination of best-practices and common trends of national RI roadmapping procedures and of ex-ante, interim (monitoring) and ex-post evaluation of RI in Europe, b) establishing a trustful dialogue and an intensive exchange of information about national RI roadmapping procedures, RI monitoring and evaluation and sustainable approaches for RI, in line with the objectives laid out in the European Research Area communication and c)fostering a dialogue with the European Commission, ESFRI, the e-IRG and all relevant stakeholders at regional, national and European levels in order to discuss the project findings and promote the dissemination of its recommendations. The InRoad activities and objectives contribute to the specific challenge highlighted in the work programme by a) promoting comparability and synchronisation of national procedures and a possible harmonisation of ex-ante and ex-post evaluation mechanisms through a survey, case studies, interviews and theoretical analyses of current frameworks in use, in close cooperation with the relevant stakeholders, b) supporting RI policy development in terms of exchange of best practices for national roadmap drafting and evaluation procedures and c) support the information sharing with stakeholders in charge of priority-setting, evaluation, funding and operation of RI through their inclusion in a dedicated Reflection Group.

GeneH proposes to create an excellence hub in gene therapy through strategic partnerships within and beyond Widening countries. Despite gene therapy's recognized priority in genomic medicine and its potential for high-curative economic impact, challenges persist in its development process, from conceptualization to commercialization. GeneH intends to address these challenges by serving as a catalyst for overcoming barriers and expediting research translation. To achieve this, GeneH will establish a robust and sustainable hub that builds upon already established ecosystems in the field and recent H2020 WIDENING projects to implement centers of excellence in gene therapy (GeneT in PT and CTGCT in SL). The academic partners at its core, namely, the University of Coimbra (UC) in Portugal and the National Institute of Chemistry (KI/NIC) in Slovenia , have reached substantial achievements by partnering with industry (Bluepharma, Biocant Park, Biosistemika, Jafral), hospitals (CHUC EPE), policy makers (CCDRC, RRA LUR), ecosystem/innovation supporters (SIH EEIG, IPN), and patient associations (APAHE, ZOPS). Partners in the two ecosystems share a common goal: treating life-threatening or chronically debilitating diseases considered incurable. By harnessing the combined expertise and resources of its partners, GeneH aims to drive cross-sectoral collaboration through its 4-helix network, in a multidimensional approach that will gather further investment, address ethical and regulatory aspects, implement de-risking approaches, educational and training programes, joint R&I programs, and prepare the path for clinical trials of new gene therapy products, while actively engaging society. By positioning itself as a leading hub in gene therapy, in line with regional, national, and European strategies, GeneH seeks to contribute to European competitive leadership globally, advancing healthcare, fostering economic growth, and making a positive societal impact.

EP PerMed is a new European Partnership dedicated to Personalised Medicine (PM). It supports PM-related R&I, but also facilitates and accelerates all steps so that PM achievements successfully pass through the full value continuum to be implemented in sustainable health systems for the benefit of people and societies. The partnership will foster demonstration projects and promote successes and lessons learned to demonstrate evidence of PM implementation. EP PerMed activities cover overarching aspects, like patient involvement, exchange with medical societies, infrastructures and international and regional collaboration. The project portfolios of EP PerMed and ERA PerMed (ERA-Net co-fund on PM) and others are supported to become successful innovations in healthcare practice. EP PerMed will be the global PM-platform for scientific and strategic dialogue and alignment, resulting in public documents and publications. Accordingly, it will inform the public, patients, healthcare providers or payers about the latest PM options and engage them. The Strategic Research and Innovation Agenda for Personalised Medicine (SRIA for PM, 2023), developed by EP PerMed partners, is the basis for the partnership's structure and a wide range of its activities. All steps of the SRIA development were strongly support by numerous PM-experts, stakeholders and the European Commission (EC). Thus, the EP PerMed annual Joint Transnational Calls (JTCs) and other funding and activities, events and tools will be in line with the SRIA and outputs will feed into a SRIA update in the coming years. The partnership builds on several developments, initiatives and projects such as ERA PerMed, ICPerMed and its supporting projects (“ICPerMed Family”) funded by the EC. In parallel, it reaches out to the 1+Million Genomes Initiative, other European Partnerships in the Health Cluster and infrastructures like the European Strategy Forum on Research Infrastructures (ESFRI).

A-AAgora aims to develop the implementable NbS (Nature based Solutions) through innovative governance structures and technological architecture. It targets to boost resilience to climate change and mitigating its impacts in coastal areas. It identifies synergies by promoting a deliberative process to complement other priority areas within the EC Mission - by setting a Community of Practice and developing a digital knowledge system. It develops NbS at three replicable demonstrators (Demo-PT, Demo-IE, Demo-NO), which can upscaled. The project seeks improved public engagement and enhanced decision-making processes at different political levels based on scientific knowledge and targeted social and economic awareness, using an EBM approach. It builds on the successful implementation of NbS at the Demo’s to which the necessary socio-technological tools will be produced as required for a realistic EBM planning cycle (up to TRL/SRL 7). The Living Lab concept will foster the exchange synergies at multiple scales between researchers and users, decision-makers and local communities, industry and SMEs. A-AAgora will demonstrate that restoration of aquatic ecosystems is possible at a large scale through reduction of pressures, EBM, and effective NbS including blue reforestation to boost coastal resilience to climate change impacts. As well, the A-AAgora will make the most of cross-Mission synergies, by targeting marine ecosystem restoration in coastal communities particularly vulnerable to the risks of sea level rise that urgently need to adapt to ensure their population and infrastructure are safe, climate-proof and weather-resilient. The design of innovative architecture, enabling interoperability with other systems and will also foster a more ‘digital ocean’.